Director James R. Tobin filed a Form 4 with the SEC on September 16, 2026, reporting the exercise of two stock option grants and the subsequent sale of 30,000 shares of Globus Medical Class A Common Stock on September 15, 2026.
Key Highlights
- Options exercised: Tobin exercised two fully vested stock option tranches, each covering 15,000 shares, at exercise prices of $53.75 and $63.68 per share, respectively.
- Shares sold: All 30,000 acquired shares were sold on September 15, 2026, at a weighted average price of $74.5834 per share.
- Sale price range: The 30,000 shares were sold in multiple transactions at prices ranging from $74.33 to $74.96, inclusive, according to the filing.
- Resulting ownership: Following all reported transactions, Tobin's direct beneficial ownership of Class A Common Stock is listed as 0 shares.
- Option grant dates: The $53.75 options were granted January 26, 2024; the $63.68 options were granted January 27, 2022, and both were fully vested at the time of exercise.
- Issuer: Globus Medical Inc, traded on NYSE:GMED.
James R. Tobin's Option Exercise and Share Sale at Globus Medical
According to the Form 4 filed on September 16, 2026, James R. Tobin, a director of Globus Medical Inc (NYSE:GMED), executed a series of transactions on September 15, 2026. Tobin exercised two separate stock option grants, each for 15,000 shares of Class A Common Stock. The first tranche carried an exercise price of $53.75 per share and was acquired via transaction code "M," bringing his direct holdings to 15,000 shares. The second tranche carried an exercise price of $63.68 per share, also coded "M," bringing his cumulative direct holdings to 30,000 shares before the sale.
On the same date, the filing reports that Tobin disposed of all 30,000 shares via an open-market sale (transaction code "S") at a weighted average price of $74.5834 per share. The filing notes that the shares were sold in multiple transactions at prices ranging from $74.33 to $74.96, inclusive, and that Tobin "undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4."
After all reported transactions, the filing reflects that Tobin's direct beneficial ownership of Class A Common Stock stands at 0 shares. The filing was signed by Kelly G. Huller as Attorney-in-Fact on September 16, 2026. No indirect ownership positions were reported in connection with these transactions.
What Was Disclosed
The filing discloses the exercise of two fully vested stock option grants totaling 30,000 shares and the same-day sale of all resulting shares by Globus Medical director James R. Tobin on September 15, 2026, leaving him with no directly held Class A Common Stock.



Please wait processing your request...